Autolus Therapeutics plc

Equities

AUTL

US05280R1005

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4 ^USD	-1.96%		-11.50%	-37.89%

Apr. 25	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	MT
Apr. 19	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	MT

Autolus Therapeutics plc Announces Resignation of Edgar Braendle, Chief Development Officer

March 14, 2024 at 12:33 pm EDT

On March 14, 2024, Autolus Therapeutics plc announced that Dr. Edgar Braendle, the Company?s Chief Development Officer, has tendered his resignation. Dr. Braendle will serve in a consulting capacity to ensure a smooth transition.

Latest news about Autolus Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	Apr. 11	MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 08	MT
European Equities Close Lower Tuesday; Eurozone Manufacturing at 3-Month Low; Mining Stocks Rally, Real Estate Drops	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
Autolus Therapeutics Gets European Agency Approval for Marketing Authorization Application for Leukemia Treatment	Apr. 02	MT
Autolus Therapeutics Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)	Apr. 02	CI
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	Apr. 02	AN
Autolus Therapeutics Appoints Mike Bonney as Chair	Apr. 01	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
Autolus Therapeutics Announces Changes to its Board of Directors	Apr. 01	CI
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	Mar. 27	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	Mar. 25	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday	Mar. 20	MT
Truist Securities Adjusts Price Target on Autolus Therapeutics to $10 From $9, Keeps Buy Rating	Mar. 18	MT
Autolus Therapeutics plc Announces Resignation of Edgar Braendle, Chief Development Officer	Mar. 14	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Mar. 14	MT
Syncona portfolio company Autolus posts widened loss for 2023	Mar. 14	AN
Transcript : Autolus Therapeutics plc, 2023 Earnings Call, Mar 14, 2024	Mar. 14
Autolus Therapeutics 2023 Net Loss Narrows, Revenue Falls	Mar. 14	MT
Autolus Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Autolus Therapeutics Receives Manufacturing Authorization, Two New Licenses for Nucleus Facility	Mar. 12	MT

Chart Autolus Therapeutics plc

Duration

Period

More charts

Company Profile

Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Autolus Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4 USD

Average target price

10.54 USD

Spread / Average Target

+163.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AUTOLUS THERAPEUTICS PLC	-37.89%	1.06B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs